Adjuvants are key factors for the development of future vaccines: Lessons from the Finlay adjuvant platform

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Pérez, Oliver ^a,b   Romeu, Belkis ^a   Cabrera, Osmir ^a   González, Elizabeth ^a   Batista Duharte, Alexander ^c   Labrada, Alexis ^d   Pérez, Rocmira ^a   Reyes, Laura M ^a   Ramírez, Wendy ^d   Sifontes, Sergio ^e   Fernández, Nelson ^f   Lastre, Miriam ^a  

^a FINLAY INSTITUTE   (Cuba)

^b Havana Medical Sciences University   (Cuba)

^c Medical University of Santiago de Cuba   (Cuba)

^d Centro Nacional de Biopreparados   (Cuba)

^e CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^f UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Adjuvant; Allergen; Cochleate; Fish; Proteoliposome; Vaccine

Indexed keywords

ADJUVANT; ALLERGEN; FC RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; T LYMPHOCYTE ACTIVATION; TH1 CELL; VACCINE PRODUCTION;

EID: 84892144204     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00407     Document Type: Article

References (101)

1. Ramon G. Sur la toxine et sur I'anatoxine diphtheriques. Ann Inst Pasteur (1924) 38:1-10.
2. Ribeiro CM, Schijns VE. Immunology of vaccine adjuvants. Methods Mol Biol (2010) 626:1-14. doi: 10.1007/978-1-60761-585-9_1.
3. Pérez O, Batista-Duharte A, González E, Zayas C, Balboa J, Cuello M, et al. Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Braz J Med Biol Res (2012) 45(8):681-92. doi:10.1590/S0100-879X2012007500067.
4. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol (2009) 9:287-93. doi:10.1038/nri2510.
5. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol (2004) 82:497-505. doi:10.1111/j.0818-9641.2004.01286.x.
6. Harandi AM, Medaglini D, Shattock RJ. Vaccine adjuvants: a priority for vaccine research. Vaccine (2010) 28(12):2363-6. doi:10.1016/j.vaccine.2009.12.084.
7. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol (2007) 5:505-17. doi:10.1038/nrmicro1681.
8. Batista-Duharte A, Portuondo D, Zeppone I, Pérez O. An approach to local immunotoxicity induced by adjuvanted vaccines. Int Immunopharmacol (2013) 17(3):526-36. doi:10.1016/j.intimp.2013.07.025.
9. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol (2000) 12:456-63. doi:10.1016/S0952-7915(00)00120-5.
10. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov (2003) 2:727-35. doi:10.1038/nrd1176.
11. Pérez O, Lastre M, Bracho G, del Campo J, Zayas C, Acevedo R, et al. Natural Neisseria derive proteoliposome and cochleate as potent vaccine adjuvants. Pharmacologyonline (2006) 3:762-4. doi:10.1016/j.ymeth.2009.03.025.
12. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol (2013) 4:1-14. doi:10.3389/fimmu.2013.00114.
13. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 203:413-24. doi:10.1084/jem.20051720.
14. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 8:769-76. doi:10.1038/ni1223.
15. Lin L, Gerth AJ, Peng SL. CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur J Immunol (2004) 34:1483-7. doi:10.1002/eji.200324736.
16. Mastelic B, Kamath AT, Fontannaz P, Tougne C, Rochat AF, Belnoue E, et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J Immunol (2012) 189:5764-72. doi:10.4049/jimmunol.1201143.
17. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 120:607-16. doi:10.1172/JCI39293.
18. Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines (2005) 4(3):329-50. doi:10.1586/14760584.4.3.329.
19. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 17(7):1055-65. doi:10.1128/CVI.00131-10.
20. Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun (2003) 71:4225-8. doi:10.1128/IAI.71.8.4225-4228.2003.
21. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol (1989) 7:145-73. doi:10.1146/annurev.iy.07.040189.001045.
22. Delves PJ, Martin SM, Burton D, Roitt I. Essential Immunology, 11th ed. Blackwell Publishing (2006).
23. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 7th ed. W.B. Saunders Co (2012).
24. Okano M, Satoskar AR, Abe M, Harn DA Jr, Okano M, Nishizaki K, et al. Interleukin-4-independent production of Th2 cytokines by nasal lymphocytes and nasal eosinophilia in murine allergic rhinitis. Allergy (2000) 55(8):723-31. doi:10.1034/j.1398-9995.2000.00429.x.
25. Yamatomo T, Okano M, Ono T, Nakayama E, Yoshino T, Satoskar AR, et al. Sex-related differences in the initiation of allergic rhinitis in mice. Allergy (2001) 56:525-31. doi:10.1034/j.1398-9995.2001.056006525.x.
26. Wheeler AW, Woroniecki SR. Immunological adjuvants in allergy vaccines: past, present and future. Allerg Int (2001) 50:295-301. doi:10.1046/j.1440-1592.2001.00230.x.
27. Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol (2013). doi:10.1016/j.jaci.2013.05.032.
28. Klimek L, Willers J, Schendzielorz P, Kündig TM, Senti G. Immunotherapy of allergic rhinitis without allergens?: New options for immunomodulation by vaccination with virus-like particles and CpG motifs. HNO (2013) 61:826-33. doi:10.1007/s00106-013-2761-9.
29. Hessenberger M, Weiss R, Weinberger EE, Boehler C, Thalhamer J, Scheiblhofer S. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores. Vaccine (2013) 31(34):3427-34. doi:10.1016/j.vaccine.2012.09.086.
30. Wolf HM, Eibl MM. The anti-inflammatory effect of an oral immunoglobulin (IgA-IgG) preparation and its possible relevance for the prevention of necrotizing enterocolitis. Acta Paediatr Suppl (1994) 396:37-40. doi:10.1111/j.1651-2227.1994.tb13240.x.
31. Honorio-França AC, Launay P, Carneiro-Sampaio M, Monteiro RC. Colostral neutrophils express Fcα receptors (CD89) lacking γ chain association and mediate noninflammatory properties of secretory IgA. J Leukoc Biol (2001) 69(2):289-96.
32. Fujihashi K, Kato H, Van Ginkel FW, Koga T, Boyaka PN, Jackson RJ, et al. A revisit of mucosal IgA immunity and oral tolerance. Acta Odontol Scand (2001) 59:301-8. doi:10.1080/000163501750541174.
33. Westerman LE, McClure HM, Jiang B, Almond JW, Glass RI. Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci U S A (2005) 102:7268-73. doi:10.1073/pnas.0502437102.
34. Lastre M, del Campo J, Cedré B, Valmaseda T, García L, Bracho G, et al. Mucosal IgA anti-lipopolysaccharide antibodies induced by 638 oral live attenuated candidate vaccine. Inmunología (2002) 21(1):3-9.
35. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ (2003) 326:365.371. doi:10.1136/bmj.326.7385.365.
36. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines (2006) 5(6):851-7. doi:10.1586/14760584.5.6.851.
37. Pletz MW, Maus U, Hohlfeld JM, Lode H, Welte T. Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance. Dtsch Med Wochenschr (2008) 133(8):358-62. doi:10.1055/s-2008-1046719.
38. Rodenburg GD, Sanders EAM, van Gils EJM, Veenhoven RH, Zborowski T, van den Dobbelsteen GPJM, et al. Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life. PLoS One (2012) 7:e46916. doi:10.1371/journal.pone.0046916.
39. Moldoveanu Z, Huang WQ, Kul-Havy R, Pate MS, Mestecky J. Human male genital tract secretions: both mucosal and systemic immune compartments contribute to the humoral immunity. J Immunol (2005) 175:4127-36.
40. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol (2013) 5:20401. doi:10.3402/jom.v5i0.20401.
41. Brandtzaeg P. Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann N Y Acad Sci (2007) 1098:288-311. doi:10.1196/annals.1384.012.
42. Cabrera O, Cuello M, Lastre M, Romeu B, Balboa J, Zayas C, et al. The golden era of vaccine adjuvants. Expert Rev Vaccines (2011) 10(7):1007-9. doi:10.1586/erv.11.62.
43. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine (2007) 25:5467-84. doi:10.1016/j.vaccine.2006.12.001.
44. De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in 325 pediatrics. Adv Drug Deliv Rev (2006) 58:52-67. doi:10.1016/j.addr.2006.01.002.
45. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 6:148-58. doi:10.1038/nri1777.
46. Lipsitch M, O'Hagan JJ. Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface (2007) 4(16):787-802. doi:10.1098/rsif.2007.0229.
47. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine (2013). 31:3363-9. doi:10.1016/j.vaccine.2013.05.007.
48. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines (2007) 6(5):723-39. doi:10.1586/14760584.6.5.723.
49. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 239:178-96. doi:10.1111/j.1600-065X.2010.00978.x.
50. Lastre M, Pérez Martín OG, Labrada A, Bidot I, Pérez J, Bracho G, et al. Allergy Vaccine Composition, Production Method Thereof and Use of Same in Allergy Treatment. WO 03/094964 A1 and Granted by Cuban Office for Intellectual Property OCPI 22983 (2004).
51. Pérez Martín OG, Bracho G, Lastre M, Sierra G, Campa C, Mora N, et al. Method of Obtaining Cochlear Structures, Vaccine Compositions, Adjuvants and Intermediates Thereof. WO/2004/047805 and Granted by Cuban Office for Intellectual Property OCPI23313 (2008).
52. Pérez Martín OG, Lastre M, Rodríguez T, Mastroeni P, Bracho G, del Campo J. Proteoliposomes and its Derivatives as Adjuvant Inducers of Citotoxic Response and the Resultant Formulation. Granted by Cuban Office for Intellectual Property OCPI CU23420 (2009).
53. Pérez O, González E, Romeu R, del Campo J, Acevedo R, Lastre M, et al. Single Time Vaccination Strategy. EP2359850 (A1) (2011).
54. Pérez Martín OG, González E, Cabrera O, Zayas C, Sifontes S, Balboa J, et al. Cochleate with Only MAMP. Patent applied to Cuban Office for Intellectual Property OCPI CU/P/2011/123 (2011).
55. Pérez Martín OG, Romeu B, Lastre M, Zayas C, González E, Balboa J, et al. Adjuvants for Polysaccharide Vaccines. Patent applied to Cuban Office for Intellectual Property OCPI CU-P-2011-2002 (2011).
56. Sierra VG, Campa HC. Preclinical and clinical studies with the antimeningococcal vaccine BC: VA-MENGOC-BC® Rev Interferon Biotechnol. Special volume (1990).
57. Sierra VG, Campa HC, Valcárcel M. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 14:195-210.
58. Huergo Concepción C, Sierra Gonzalez VG, Gutiérrez Vázquez MM, Bisset Jorrin G, Garcia Imia LG, de la Caridad Puentes Rizo G, et al. Method of Producing Neisseria meningitidis B Vaccine, and Vaccine Produced by Method. Granted US Patent No. 5597572 (1997).
59. Sierra VG, Campa C, García L, Sotolongo F, Izquierdo L, Valcárcel M. Efficacy evaluation of the Cuban vaccine VA-MENGOC-BC® against disease caused by serogroup B Neisseria menigitidis. Proceedings of the 7th International Pathogenic Neisseria Conference. Berlin: Walter de Gruyter & Co (1990). p. 129-34.
60. Lapinet JA, Scapini P, Calzetti F, Pérez O, Cassatella MA. Gene expression and production of tumor necrosis factor alpha, interleukin-1beta (IL-1beta), IL-8, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles. Infect Immun (2000) 68(12):6917-23.
61. Pérez O, Lastre M, Lapinet J, Bracho G, Padrón J, Díaz M, et al. Immune response induction and new effector mechanisms possibly involved in protection of cuban anti-meningococcal BC vaccine. Infect Immun (2001) 69(2001):4502-8. doi:10.1128/IAI.69.7.4502-4508.2001.
62. Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol (2007) 66:271-7. doi:10.1111/j.1365-3083.2007.01981.x.
63. Rodríguez T, Pérez O, Menager N, Ugrinovic S, Bracho G, Mastroeni P. Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery. Vaccine (2005) 23:1312-21. doi:10.1016/j.vaccine.2004.07.049.
64. Muralinath M, Kuehn MJ, Roland KL, Curtiss R III. Immunization with Salmonella enteric serovar typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against hallenge with Streptococcus pneumoniae. Infect Immun (2011) 79:887-94. doi:10.1128/IAI.00950-10.
65. Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholera outer membrane vesicles induces protective immunity in mice. Infect Immun (2008) 76:4554-63. doi:10.1128/IAI.00532-08.
66. Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci U S A (2010) 107:3099-104. doi:10.1073/pnas.0805532107.
67. Dull PM, McIntosh ED. Meningococcal vaccine development-from glycoconjugates against MenACWY to proteins against MenB-potential for broad protection against meningococcal disease. Vaccine (2012) 30(Suppl 2):B18-25. doi:10.1016/j.vaccine.2012.01.062.
68. Novartis. Novartis Receives EU Approval for Bexsero®, First Vaccine to Prevent the Leading Cause of Life-Threatening Meningitis Across Europe (2013). Available from: http://hugin.info/134323/R/1672036/543712.pdf.
69. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med (2011) 365:186375. doi:10.1056/NEJMoa1102287.
70. Pérez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D, et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol (2004) 82:603-10. doi:10.1111/j.1440-1711.2004.01293.x.
71. del Campo J, Lastre M, Bracho G, Rodríguez T, Gil D, Zayas C, et al. Immunological evaluation of bacterial derived cochleate and proteoliposome as mucosal adjuvants. Vaccine (2006) 24(Suppl 2):50. doi:10.1016/j.vaccine.2005.01.119.
72. del Campo JM, Zayas C, Romeu B, Acevedo R, González E, Bracho G, et al. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods (2009) 49:301-8. doi:10.1016/j.ymeth.2009.03.025.
73. del Campo J, Lindqvist M, Cuello M, Bäckström M, Cabrera O, Persson J, et al. Intranasal immunization with a proteoliposomederived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine (2010) 28:1193-200. doi:10.1016/j.vaccine.2009.11.035.
74. Gould-Fogerite S, Mannino RJ. Cochleates for induction of mucosal and systemic immune responses. In: O'HaganDT editor. Vaccine Adjuvants in Methods in Molecular Medicine. Preparation Methods and Research Protocols. Totowa, NJ: Humana Press (2000). p. 179-96.
75. Lastre M, Pérez O, Labrada A, Bidot I, Pérez J, Bracho G, et al. Bacterial derived proteoliposome for allergy vaccines. Vaccine (2006) 24(Suppl 2):S2-5. doi:10.1016/j.vaccine.2005.01.110.
76. Chen X, Fernando GJP, Crichton ML, Flaim C, Yukiko SR, Fairmaid EJ, et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release (2011) 152:349-55. doi:10.1016/j.jconrel.2011.02.026.
77. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol (2009) 21:346-51. doi:10.1016/j.coi.2009.05.016.
78. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One (2013) 8(3):e57726. doi:10.1371/journal.pone.0057726.
79. González E, Romeu B, del Campo J, Acevedo R, Lastre M, Zayas C, et al. Mucosal and systemic immune response against Neisseria meningitidis B induced by single time vaccination strategy. Vaccimonitor (2009) 18(2):73-5.
80. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res (2003) 338:2539-47. doi:10.1016/j.carres.2003.07.008.
81. Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria-new potentials for conjugate vaccines? Scand J Immunol (2003) 58:119-28. doi:10.1046/j.1365-3083.2003.01292.x.
82. Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccine. 5th ed. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia: Saunders (2008). p. 569-604.
83. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein polysaccharide conjugate vaccines. Nat Rev Immunol (2009) 9:213-20. doi:10.1038/nri2494.
84. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis (1995) 21:616-20. doi:10.1093/clinids/21.3.616.
85. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis (2010) 50(Suppl 2):S45-53. doi:10.1086/648964.
86. Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malar J (2009) 27(8):35. doi:10.1186/1475-2875-8-35.
87. Guilherme E, Postol S, Freschi de Barros F, Higa R, Alencar, Lastre M, Zayas C, et al. A vaccine against S. pyogenes: design and experimental immune response. Methods (2009) 49:316-21. doi:10.1016/j.ymeth.2009.03.024.
88. Romeu B, González E, Zayas C, del Campo J, Acevedo R, Cuello M, et al. AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses. Scand J Infect Dis (2011) 43:809-13. doi:10.3109/00365548.2011.586648.
89. Pérez O, Romeu R, del Campo J, Zayas C, Lastre M. Proteoliposome and polysaccharide-based meningococcal vaccine are immunogenic in infants and toddlers and primes for memory against serogroup C polysaccharide. WJV (2013) 3(2):77-87. doi:10.4236/wjv.2013.32012.
90. Romeu B, Lastre M, García L, Cedré B, Mandariote A, Fariñas M, et al. Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A. Immunol Res (2013). doi:10.1007/s12026-013-8427-6.
91. Avci F, Li X, Tsuji M, Kasper D. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med (2011) 17:1602-9. doi:10.1038/nm.2535.
92. World Aquaculture. FAO Fisheries and Aquaculture Department. Technical Paper No. 500/1. Rome: FAO (2010). 105 p.
93. Davis CR, Okihiro MS, Hinton DE. Effects of husbandry practices, gender, and normal physiological variation on growth and reproduction of Japanese medaka, Oryzias latipes. Aquat Toxicol (2002) 60:185-201. doi:10.1016/S0166-445X(02)00004-8.
94. Tort L, Balasch JC, MacKenzie S. Fish immune system. A crossroads between innate and adaptive responses. Inmunología (2003) 22:277-86.
95. Dimitroglou A, Merrifield DL, Moate R, Davie SJ, Spring P, Sweetman J, et al. Dietary mannan oligosaccharide supplementation modulates intestinal microbial ecology and improves gut morphology of rainbow trout, Oncorhynchus mykiss (Walbaum). J Anim Sci (2009) 87:3226-34. doi:10.2527/jas.2008-1428.
96. Traifalgar RFN, Corre VL, Serrano AE. Efficacy of dietary immunostimulants to enhance the immunological responses and vibriosis resistance of juvenile Paneus monodon. J Fish Aquat Sci (2013) 8(2):340-52. doi:10.3923/jfas.2013.340.354.
97. Iliev D, Roach J, MacKenzie S, Planas J, Goetz F. Endotoxin recognition: in fish or not in fish? FEBS Lett (2005) 579:6519-6528. doi:10.1016/j.febslet.2005.10.061.
98. Kadowaki T, Yasui Y, Nishimiya O, Takahashi Y, Kohchi C, Soma G, et al. Orally administered LPS enhances head kidney macrophage activation with down-regulation of IL-6 in common carp (Cyprinus carpio). Fish Shellfish Immunol (2013) 34(6):1569-75. doi:10.1016/j.fsi.2013.03.372.
99. Selvaraj V, Sampath K, Sekar V. Adjuvant and immunostimulatory effects of beta-glucan administration in combination with lipopolysaccharide enhances survival and some immune parameters in carp challenged with Aeromonas hydrophila. Vet Immunol Immunopathol (2006) 114:15-24. doi:10.1016/j.vetimm.2006.06.011.
100. Jinhui S, Qingkui W, Zhiyi Q, Dongqing B, Jingfeng S, Xiuting Q. Effect of lipopolysaccharide (LPS) and outer membrane protein (OMP) vaccines on protection of grass carp (Ctenopharyngodon idella) against Aeromonas hydrophila. Israeli J Aquac Bamidgeh (2011) 63:8.
101. Nayak SK, Swain P, Nanda PK, Mohapatra D, Behera T. Immunomodulating potency of lipopolysaccharides (LPS) derived from smooth type of bacterial pathogens in Indian major carp. Vet Microbiol (2011) 151(3-4):413-7. doi:10.1016/j.vetmic.2011.03.021.